COVID-19 Testing: PCR (Diagnostic) vs Antibody

Home - Biochip

COVID-19 Testing: PCR (Diagnostic) vs Antibody

News       About Us       Randox Health

 

18 June 2020

COVID-19 Testing: PCR (Diagnostic) vs Antibody

The advice from the World Health Organisation in relation to the COVID-19 pandemic has been simple; Test. Test. Test.

But what are the different types of COVID-19 tests and what are they used for?

 

Diagnostic (PCR) Testing

This type of testing detects SARS-CoV-2 (the virus that causes COVID-19) within the body and will tell you if you currently have COVID-19. PCR tests cannot tell you if you have had past infection.

Sample collection for a PCR test can vary, though it is usually in the form of a swab, which will gather an individual’s nasopharyngeal (nose and throat) secretions.

PCR tests for COVID-19 all use methods that detect a specific part of the viral genome – for example Viral RNA or Antigen.  

A sample is prepared by extracting the chosen section of the genome, and then PCR (Polyamerase Chain Reaction) techniques are used to amplify (replicate) the genome section, ready for detection.

Viral RNA Tests

This type of test detects the RNA (Ribonucleic acid) contained within the SARS-CoV-2 virus.

It is this type of test, for RNA, that is recommended by The World Health Organisation for COVID-19 diagnosis.

Antigen Tests

Antigens are molecular structures on the surface of viruses that are recognized by the immune system and are capable of triggering an immune response.

Antigen tests detect the presence of the SARS-CoV-2 virus by looking for the antigen on the surface of the virus.

Randox COVID-19 Test

The Randox COVID-19 test, as recommended by the World Health Organisation, detects the RNA contained within the SARS-CoV-2 virus.

After sample extraction and amplification, the virus is detected on our patented Randox Biochip Technology platform.

The Randox Biochip, which can run multiple tests simultaneously, performs two tests for COVID-19 – one specific and one confirmatory – as recommended by the WHO. This delivers extra assurance of the correct diagnosis and avoids the need to repeat the test.

 

Antibody (Serology) Tests

Antibody (also known as serology) tests, are usually performed on a patient blood sample, and look for antibodies (a type of protein) that may have been developed by the patient’s immune system to fight off disease.

If present, antibodies may provide a degree of immunity for the patient against COVID-19 in the future.

However, there is still much unknown about the body’s antibody response to COVID-19, including;

  • Whether all patients who have been infected with SARS-CoV-2 will generate antibodies (recent studies and news reports indicate that this isn’t the case. Click here for an example.)
  • Whether those who have had more severe symptoms as a result of COVID-19 will produce more antibodies than those who had mild symptoms, or were asymptomatic.
  • If antibodies from other coronaviruses previously experienced by the patient may be enough to fight off the virus, therefore eliminating the need for COVID-19 specific antibodies.
  • How long any COVID-19 specific antibody response will last for.
  • How much future immunity is provided by COVID-19 antibodies. Will it prevent the patient from being infected, or will future infection just be less severe?

If antibodies for the SARS-CoV-2 virus are present this can give an indication that the patient has been previously infected with COVID-19. Antibody tests do not confirm the real-time presence of the virus in your system.

For example, a negative antibody result does not necessarily mean the body has not been exposed to the SARS-CoV-2 virus. It could in fact, be currently infected, but has not yet generated antibodies. A diagnostic test will confirm current presence of the virus.

 

Therefore, it is recommended that antibody tests are used in tandem with a diagnostic test to determine a complete overview of the patient’s COVID-19 status.

Randox Health currently offers both diagnostic testing and antibody testing for SARS-CoV-2 (COVID-19).

A combination of diagnostic and antibody testing is available for individual purchase, or as part of our ‘Back to Business’ COVID-19 testing service, for staff screening.

Visit Randox Health to find out more.

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our Randox Products and Services

REAGENTS

RX SERIES

ACUSERA

BIOCHIP


COVID-19 Laboratory Tools for Disease Management

News       About Us       COVID-19 Lab Tools

17 June 2020

COVID-19 – Laboratory Tools for Disease Management

In addition to tests for the detection of SARS-CoV-2, the virus that causes COVID-19, laboratory diagnostics play a pivotal role in patient management, risk stratification, monitoring of disease progression, associated complications and response to treatment.

Randox offers a comprehensive range of laboratory solutions including; diagnostics reagents, revolutionary Biochip technology and quality control designed to provide clinicians with valuable insights into disease severity ultimately helping to improve patient care.

Patients with comorbidities such as diabetes mellitus, cardiovascular disease (CVD) and chronic kidney disease (CKD) are particularly susceptible to COVID-19 infection and are at greater risk of developing severe illness.  The Randox portfolio may also be used to diagnose and monitor such at risk patients with underlying health concerns.

 

Biochemistry Reagents

Our extensive test menu comprises 113 assays, including many unique tests and a range of biomarkers designed to assist laboratories when screening for a variety of COVID-19 related health issues.

Randox Reagents are internationally recognised as being of the highest quality; producing accurate and precise results.  Applications are available detailing instrument-specific settings for the majority of clinical chemistry analysers.

C-Reactive Protein (CRP)

Elevated markers of inflammation and infection such as CRP may indicate severe viral infection. CRP is elevated in up to 86% of COVID-19 patients who are admitted to hospital. Testing for CRP is useful in assessing prognosis, and when monitoring improvement. It is recommended that CRP is measured at baseline and then at intervals, a sudden increase in levels will prompt surveillance for secondary infection or other cause of deterioration.

Ferritin

As an acute phase reactant, Ferritin levels increase in response to inflammation. High levels have been identified in approximately 60% of individuals hospitalised as a result of COVID-19 infection. In critically ill patients, elevated Ferritin levels may be indicative of a cytokine storm and secondary haemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome associated with organ failure.

Liver Function Tests (Albumin, ALT, AST, Bilirubin)

Patients with COVID-19 may be at higher risk of liver injury or impairment of liver function. Liver function markers such as ALTAST and Bilirubin are notably higher in more severe infections, decreased albumin levels have also been documented in severe cases. Drug induced liver injury as a result of COVID-19 treatment should not be ignored and should be monitored.

Renal Function Tests (Creatinine, Cystatin C)

Emerging evidence suggests that SARS-CoV-2 may directly affect kidney function, as such COVID-19 patients should be assessed for Acute Kidney Injury (AKI) on admission to hospital and monitored throughout their stay. AKI can lead to worse outcomes for patients.

Lactate Dehydrogenase (LDH)

LDH levels may be a convenient marker for the identification of COVID-19 patients at higher risk of developing severe respiratory failure. It is well documented that high LDH levels are indicative of haematological malignancy and acute lung injury. LDH levels might therefore reflect tissue necrosis related to immune hyperactivity and thus are related to poor clinical outcomes in individuals with COVID-19.

G6PDH

Chloroquine has been investigated as a potential treatment for COVID-19, the anti-malaria drug however could have devastating consequences for those with a G6PDH deficiency. G6PDH deficiency is a genetic disorder affecting the red blood cells, causing them to break down prematurely. The most common complication of deficiency is haemolytic anaemia. An estimated 400 million people globally have G6PDH deficiency, it is most common in certain parts of Africa, Asia, the Mediterranean and Middle East.

 

Randox Biochip Solutions

Randox Biochip technology is extremely versatile with applications in not only the diagnosis of COVID-19 but also the identification of individuals at risk of developing more severe illness.  

Unique to Randox, Biochip technology is capable of simultaneous detection of a panel of  related disease markers.  An extensive range of  Biochip panels are available, each optimised to provide the best performance.

Cytokine Arrays

Cytokines play a vital role in the immune system and are known to be involved in the body’s response to a variety of inflammatory and infectious diseases. The over stimulation of these cytokines in response to infection is referred to as a ‘cytokine storm’ and strongly correlates with poor disease outcomes. Cytokine storms are a common complication of SARS-CoV-2 infection triggering viral sepsis, where viral replication and excessive, uncontrolled systemic inflammation may lead to pneumonitis, Acute Respiratory Distress Syndrome (ARDS), respiratory failure, shock, multiple organ failure, secondary bacterial pneumonia, and potentially death. Cytokines such as IL-6 appear to be elevated in patients with more severe illness and may be used to monitor response to treatment as levels decrease as the condition improves.

 

Quality Control Solutions

Randox offer a range of Quality control and External Quality Assessment (EQA) solutions designed to ensure the accuracy and reliability of patient testing.

Haematology

Decreased blood counts have been frequently identified in COVID-19 patients and may be indicative of a decreased immunological response to the virus, bacterial infection or consumption.

Blood Gas

Blood Gas tests are used to help diagnose and monitor critically ill patients in intensive care units (ICU) and emergency departments. Blood Gas testing continues to play a critical role in the management of COVID-19 patients providing an indication of a patient’s oxygenation levels. Monitoring of these levels will enable healthcare professionals to make ventilator adjustments if required.

Cardiac Markers

Increased levels of cardiac markers including Troponin and CK-MB may be associated with a higher mortality rate in COVID-19 patients.

Coagulation

Patients with severe COVID-19 infection are more likely to have coagulopathy, a condition in which the bloods ability to form clots is impaired. Activation of blood coagulation factors such as Prothrombin Time (PT) and D-dimer are significant predictors of disease severity and mortality.

Procalcitonin

Procalcitonin is an acute phase reactant released by most tissues during inflammation and is particularly associated with bacterial infection. Although it is not usually elevated in viral infections such as SARS-CoV-2 levels may increase as a result of severe systemic inflammation. It may also be used to help detect secondary infections.

For further information about any of the above Laboratory Tools for COVID-19 Disease Management please email marketing@randox.com

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our Randox Products and Services

REAGENTS

RX SERIES

ACUSERA

BIOCHIP


Cytokine testing for COVID-19 risk stratification and treatment monitoring

News       About Us       Cytokine Biochips

 

11 June 2020

Cytokine testing for COVID-19 risk stratification and treatment monitoring

On Biomedical Science Day 2020, an innovative method of monitoring treatment efficacy and recovery of COVID-19 has been unveiled by global diagnostics company Randox Laboratories.

The test, which looks for the presence of cytokines (a type of small protein) is performed on Randox’s patented Biochip Technology, which can simultaneously detect multiple analytes from a single patient sample.

Cytokines play a vital role in the immune system and are known to be involved in the body’s response to a variety of inflammatory and infectious disease, such as COVID-19.

Lynsey Adams, Randox Marketing Manager, commented;

“Cytokine storms, which are the overstimulation of cytokines in response to infection, are a common complication of severe cases of COVID-19, and can trigger excessive, uncontrolled systemic inflammation.

“The monitoring of cytokine proteins therefore offers a unique opportunity to identify patients who, as a result of this viral sepsis, are at risk of poor disease outcomes including pneumonitis, Acute Respiratory Distress Syndrome, respiratory failure, shock, or even organ failure.

“Treatment for any infection, COVID-19 included, is most effective when administered at an early stage, and so the detection of cytokine storms within COVID-19 patients could provide vitally important information that will direct the appropriate patient care pathway and facilitate improved patient outcomes.”

The comprehensive cytokine testing menu from Randox comprises of 26 different cytokines, across four different biochip panels.

Designed to make cost, time and resource savings for a range of diagnostic laboratories, Randox Cytokine Biochips can detect up to 12 cytokines and growth factors from a single patient sample.

Lynsey continued;

 “The multiplex capabilities of the Randox Biochip will provide clinicians with a more comprehensive picture of the patient’s condition.

“Compatible with our Evidence and Evidence Investigator analysers, which are capable of processing 2960 and 2376 tests per hour respectively, Randox Cytokine Biochip panels offer a comprehensive testing method for these proteins which play such a central role in the immune system.”

In addition to COVID-19 risk stratification, cytokine testing has also been linked to monitoring for allergies, vascular diseases, cancer, and a range of autoimmune diseases.

Key Benefits of Randox Cytokine Testing

  • Simultaneous detection of up to 12 cytokines and growth factors from a single patient sample
  • Fully automated and semi-automated testing platforms available to suit all laboratory throughputs
  • Comprehensive test menu comprising 26 cytokines, cytokine receptors and growth factors
  • Suitable for use with serum and plasma samples
  • Excellent analytical performance
  • Availability of complementary quality controls for a complete testing package

For more info please visit www.randox.com/cytokine-testing-solutions/, email marketing@randox.com or phone 028 9442 2413

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our Randox Products and Services

REAGENTS

RX SERIES

ACUSERA

BIOCHIP


The Drug Epidemic in The Seychelles Islands

News       About Us        Randox Toxicology

24 December 2019

 

The Drug Epidemic in The Seychelles Islands

The Seychelles is suffering from a drug epidemic. Nearly 10% of its 94000 population are addicted to heroin, according to the Agency for the Prevention of Drug Abuse and Rehabilitation (APDAR) in the Seychelles.

Per capita, the Seychelles suffers from the highest rate of heroin abuse in the world. Heroin makes the long journey from Central Asia, especially Afghanistan, before being smuggled to the islands via East Africa. Made up of 115 islands, the Seychelles has many porous borders, which makes them hard to monitor and easy for the drugs to come into the country. Rather than attempting a “war on drugs”, which would criminalise the large proportion of heroin users in the Seychelles, the head of the anti-drug agency has introduced a Portuguese-style drug policy – considering drug addiction as a chronic diseased to be treated.

Heroin users in the Seychelles have two options:

  • Join a high threshold Methadone Maintenance Programme (MMP), which includes a period of in-patient treatment where they must commit to detoxification
  • Or the low threshold programme, which focuses on harm reduction

Individuals have access to medical and psychosocial support under both programmes.

Patrick Herminie, who had previously attended one of the programmes, has stated “currently, we have over 2000 people registered in one of our programmes and 68% of those are now gainfully employed”.  Each morning he visits one of the country’s mobile methadone clinics, white vans that are manned by drug counsellors and qualified nurses to give the correct dose of methadone to recovering addicts. People line up outside the open windows of the van, ready to show their ID. Their name, the date and time are logged into a spreadsheet on receipt of the information and the correct dose of methadone is distributed to them.

Utilising our patented Biochip Array Technology, our DoA ULTRA panel, available for the Evidence Investigator, offers the most comprehensive drugs of abuse screen across multiple forensic matrices. Detecting up to 20 targets drugs including heroin and other opioids, it has the largest cross-reactivity profile of over 240 analytes. Our excellent assay precision and performance eliminates false reporting, offering CVs of typically <10%. Randox Toxicology produce an accurate drug profile to ensure confidence in results.

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


Drug Abuse Screening in the Emergency Department

News       About Us        Randox Toxicology

21 October 2019

 

Drug Abuse Screening in the Emergency Department

On a global scale, emergency departments have been providing critical access to the health care system for many years, however, more recently visits to the emergency department has been an opportunity to identify patients with substance use disorders. Screening patients for illicit drugs and drug abuse has become increasingly more regular when a patient is admitted to the emergency department. Screening is vital to treat a patient with effective treatment. Nearly half of all emergency department visits in the US are categorized as relating to substance use disorders.

In a study completed at Ghent University Hospital in 2017  it was found that the most frequently reported drugs abused by emergency department patients are cannabis, cocaine, amphetamines, and opiates. It is important to screen patients in the emergency department if the patient is showing signs of confusion, deliriousness, unconsciousness, panic attacks, chest pain, difficulty breathing, vomiting, or seizures as these symptoms usually indicate drug intoxication or overdose.

Randox Toxicology’s Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 21 analytes from a single sample, making it ideal for an emergency department. It requires a small sample volume and generates results in 20 minutes. The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error. The MultiSTAT is designed to analyse as quick, simple and reliable as possible.

 

Available Tests
AB-CHMINACA AB-PINACA Amphetamine
Barbiturates Benzodiazepines I (Oxazepam) Benzodiazepines II (Lorazepam)
Benzoylecgonine (Cocaine Metabolite) Buprenorphine Cannabinoids (THC)
Creatinine Ethyl Glucuronide (EtG) Fentanyl
LSD Methadone Methamphetamine
Opiate Oxycodone Phencyclidine (PCP)
Pregabalin Propoxyphene Tramadol
Tricyclic Antidepressants (TCA) UR-144/XLR-11 α-PVP (Flakka)

 

If you would like to find out more about the Evidence MultiSTAT, Biochip Array Technology, or our Evidence range of analysers, contact info@randoxtoxicology.com or visit www.randoxtoxicology.com

 

Visit Randox Toxicology

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


World Heart Day from Randox Biosciences

News       About Us        Randox Biosciences

29 September 2019

 

World Heart Day 2019

 

The World Heart Federation (WHF) is the acting global voice in leading the universal fight against cardiovascular disease (CVD).  Part of the WHF mission is to ensure heart health equity for everyone. They believe everybody is entitled to cardiovascular health and well-being through health promotion, access to prevention, control and management of CVD 1.

World Heart Day falls on the 29th September where people make a promise to promote and implement healthier lifestyles to maintain a happy and healthy heart, reducing the potential risks of heart disease and stroke.  CVD takes the lead being the number one cause of death world-wide 2 relating to all heart and circulatory diseases consisting of coronary heart disease, angina, heart attack, congenital heart disease, hypertension, stroke and vascular dementia 3.

According to the World Health Organisation2:

  • An estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.
  • Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by CVD.
  • Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use, unhealthy diet and alcohol abuse.
world-heart-day-2019

Cytokines have a central role within the immune system; they are a category of signalling molecules that mediate and regulate immunity, inflammation and hematopoiesis 4.  Cytokine and inflammatory mechanisms have major implications for the vascular system and can lead to CVD.

Cytokines exist in broad families that are structurally related but exhibit diverse function.  The major classes of cytokines include: pro- and anti-inflammatory cytokines, cytokines of neutrophil and eosinophil recruitment and activation, cytokines derived from T-helper (Th) and T-regulatory (Tregs) cells, and cytokines of T-cell recruitment and growth factors.

Randox offers a comprehensive menu of 26 cytokine, cytokine receptors and growth factors over four multi-analyte arrays.  Each cytokine assay is performed on biochip array technology with spatially discrete test regions containing antibodies specific to each of the analytes.  The combination of highly specific antibodies and advanced chemistries enables up to 12 cytokines and growth factors to be detected simultaneously in a single sample.

Cytokine Array I                                                            Cytokine Array III

  • Epidermal Growth Factor (EGF) –    Granulocyte Macrophage Colony Stimulating
  • Interferon-y –    Interleukin-5
  • Interleukin-1a –    Interleukin-15
  • Interleukin-1b –    Macrophage Inflammatory Protein-1a
  • Interleukin-2
  • Interleukin-4
  • Interleukin-6
  • Interleukin-8
  • Interleukin-10
  • Monocyte Chemotactic Protein-1
  • Tumour Necrosis Factor-a
  • Vascular Endothelial Growth Factor

Cytokine Array IV                                                                         Cytokine Array V

  • Matrix Metalloproteinase-9 –    Interleukin-3
  • Soluble IL-2 Receptor a –    Interleukin-7
  • Soluble IL-6 Receptor –    Interleukin-13
  • Soluble Tumour Necrosis Factor Receptor I –   Interleukin-12 p70
  • Soluble Tumour Necrosis Factor Receptor II –   Interleukin-23

Key Benefits of Randox Cytokine Arrays:

  • Multiplex testing from a single sample.
  • Suitable for human serum and plasma samples.
  • Small sample volume required.
  • Excellent analytical performance.
  • Fast throughput.
  • Applicable to fully automated and semi-automated Evidence analysers.

Randox manufacture the majority of assay raw materials in-house and can therefore take a more tailored approach, by adapting assays to the needs of your research project to best fit your individual requirements.

  1. https://www.world-heart-federation.org/
  2. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  3. https://www.bhf.org.uk/informationsupport/conditions/cardiovascular-disease
  4. https://www.sinobiological.com/cytokine-rerview-receptor-source-targets-main-function-disease-association-a-1310.html
  5. https://www.sciencedirect.com/topics/neuroscience/cytokines
Visit Randox Biosciences

Randox Biosciences Products and Services

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS

Want to know more about Randox?

Contact us or visit our homepage to view more.


Metabolic Syndrome Arrays from Randox Biosciences

News       About Us        Randox Biosciences

17 September 2019

 

Metabolic Syndrome Arrays from Randox Biosciences

 

Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.

This serious health condition is very common, and studies state that it affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.

Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.

1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:

-Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)

-Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater

– HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women

– Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater

There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.

Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.

 

 

metabolic syndrome

Metabolic Syndrome Array I

  • Ferritin
  • Interleukin-6 (IL-6)
  • Insulin
  • Leptin
  • Plasminogen Activator Inhibitor-1 (PAI-1)
  • Resistin

Metabolic Syndrome Array II

  • Adiponectin
  • C-reactive Protein (CRP)
  • Cystatin C

Want to know more about Randox?

Contact us or visit our homepage to view more.


Multiplex biochip for accurate differentiation of stroke types launched at AACC

Stroke        Biochip        MultiSTAT

05 August 2019

Stroke Biochip

 

A ground-breaking new test which improves the accuracy of stroke diagnosis has been developed by Randox scientists.

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

With a unique ability to differentiate between ischaemic and haemorrhagic stroke, the Randox Stroke Biochip takes less than 30 minutes to complete – making sure patients get the right diagnosis as fast as possible.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, whose team developed the test, commented;

“There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time, yet too often the window closes before a diagnosis is made. For doctors, nothing is more frustrating.

“Excellent work has been undertaken to assist the public in recognising the signs of a stroke so people can get to hospital as quickly as possible. Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

 

Benefits of the Randox Stroke Biochip

  • Results in 30 minutes on the Evidence MultiSTAT
  • Unique solution for stroke classification
  • Differentiation of ischaemic and haemorrhagic stroke
  • Guarantees rapid thrombolytic therapy ensuring better patient outcomes

 

John Lamont, R&D Director for Randox Laboratories, explained the benefits of the Stroke Biochip;

 “While patients undergo a CT scan to confirm either the presence or lack of a haemorrhagic stroke, a blood test on the Randox Biochip can be run on our innovative point-of-care analyser, the Evidence MultiSTAT, to identify the same for an ischaemic stroke.

“For the almost 90% of stroke patients who are ruled out for haemorrhagic stroke1, the Randox Biochip will then accelerate decision making for clinicians with regards to thrombolytic therapy.

 “Any treatment is most effective if started as soon as possible after the stroke occurs, and so every minute that passes without a diagnosis is likely to leave a permanent mark on a stroke patient’s future health and lifestyle.  The vitally important diagnostic information from the Randox Stroke Biochip facilitates accurate stroke classification, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy, ensuring a better patient outcome for ischaemic stroke sufferers, for whom time is of the essence.”

Whilst the Randox Stroke Biochip is currently being used as complementary testing in parallel with CT scanning, Mr Lamont is confident of a more prominent role for the test in the future patient pathway;

“The Biochip has the potential to really revolutionise the stroke diagnosis pathway as we currently know it. The accessibility of this type of blood testing could potentially extend its use beyond the A&E department, to ambulances and even the home, in the form of a hand-held testing device.”

For further information about our pioneering Stroke Biochip please visit us at stand 1101 at this year’s AACC or follow the links below.

 

Want to know more?

Contact us or visit our Stroke Biochip page to learn more.

Related Products

MULTISTAT

EVIDENCE SERIES

BIOCHIP

CEREBRAL ARRAY


New test for accurate differentiation of stroke types launched at Goodwood FOS Future Lab

A ground-breaking new test which improves the accuracy of stroke diagnosis has been developed by Randox scientists.

The rapid and highly sensitive blood test, which is due to be unveiled at this year’s Goodwood Festival of Speed, can uniquely differentiate between ischaemic strokes (a blood clot) and haemorrhagic strokes (a bleed) and subsequently enable clinicians to rapidly administer the most effective treatment, which is a vital factor in limiting permanent damage.

What’s even more remarkable is that the pioneering diagnostic, appearing as part of the festival’s Future Lab exhibition, takes less than 30 minutes to complete – making sure patients get the right diagnosis as fast as possible.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, whose team developed the test, commented;

“There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time, yet too often the window closes before a diagnosis is made. For doctors, nothing is more frustrating.

“Excellent work has been undertaken to assist the public in recognising the signs of a stroke so people can get to hospital as quickly as possible. Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”

Traditionally the first step in a stroke diagnosis is a CT scan, which, despite its ability to successfully diagnose haemorrhagic stroke, is significantly less capable of identifying ischaemic stroke.

Yet ischaemic stroke is the most common type of stroke and affects almost nine in ten patients.  Its diagnosis and differentiation from haemorrhagic stroke is vital in enabling thrombolytic treatment to break down blood clots, which, given its nature, could be fatal if administered to a patient suffering from a haemorrhagic stroke. Worryingly though, in some areas of the UK, as little as 15% of eligible stroke patients receive this therapy in time.1

This is caused by a number of factors, including difficulty in determining stroke onset time, exceeding the appropriate time window for thrombolysis administration (4.5 hours from stroke onset), and importantly, not being able to differentiate ischaemic stroke from a number of other ‘stroke mimics’ including severe migraine, brain tumours, drug overdose and seizures.

The Randox Stroke Biochip successfully identifies ischaemic stroke in a rapid test which measures eight markers from a single blood sample simultaneously, in just 30 minutes.

John Lamont, R&D Director for Randox Laboratories, explained;

 “While patients undergo a CT scan to confirm either the presence or lack of a haemorrhagic stroke, a blood test on the Randox Biochip can be run on our innovative point-of-care analyser, the MultiSTAT, to identify the same for an ischaemic stroke.

“For the almost 90% of stroke patients who are ruled out for haemorrhagic stroke2, the Randox Biochip will then accelerate decision making for clinicians with regards to thrombolytic therapy.

 “Any treatment is most effective if started as soon as possible after the stroke occurs, and so every minute that passes without a diagnosis is likely to leave a permanent mark on a stroke patient’s future health and lifestyle.  The vitally important diagnostic information from the Randox Stroke Biochip facilitates accurate stroke classification, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy, ensuring a better patient outcome for ischaemic stroke sufferers, for whom time is of the essence.”

Whilst the Randox Stroke Biochip is currently being used as complementary testing in parallel with CT scanning, Mr Lamont is confident of a more prominent role for the test in the future patient pathway;

He commented;

“The Biochip has the potential to really revolutionise the stroke diagnosis pathway as we currently know it. The accessibility of this type of blood testing could potentially extend its use beyond the A&E department, to ambulances and even the home, in the form of a hand-held testing device.”

For further information about our pioneering new stroke test, or about the Goodwood Festival of Speed Future Lab, please contact Amy McIlwaine in the Randox PR team by emailing amy.mcilwaine@randox.com 

References

1 Royal College of Physicians Sentinel Stroke National Audit Programme (SSNAP). Clinical audit Jan – Mar 2016 report prepared by Royal College of Physicians, Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party.

2 Intercollegiate Stroke Working Party. National clinical guideline for stroke, 5th edition. London: Royal College of Physicians 2016.

 

 

 

 

 

 

 

 

 

 


Alzheimer’s Disease testing on the Randox Evidence Series

What is Alzheimer’s Disease?

Alzheimer’s Disease is a progressive disease and is one of the most common kinds of dementia.

Our brains are made up of billions of tiny nerve cells which connect to each other. However, if you have Alzheimer’s Disease the connections between the cells are lost, which results in the loss of brain tissue and causes nerve cells to die1.

The brain is responsible for sending signals between cells. Those who suffer with Alzheimer’s have less ‘chemical messengers’ in their brain, so the signals are not passed on as well1.

The statistics of those who suffer with dementia is increasingly high and the figure is set to rise in the foreseeable future. Over 850,000 people are living with dementia in the UK. Studies states that one million people in the UK will have dementia in 2025 and this will increase to two million by 2050.2

Symptoms of Alzheimer’s Disease

The symptoms of Alzheimer’s disease are divided into 3 main stages; early symptoms, middle-stage symptoms and later symptoms.

In the early stages, the main symptom of Alzheimer’s disease is memory lapses which can increase anxiety or agitation. In the early stages, it is often mistaken that the person is forgetful and aren’t aware they are suffering with Alzheimer’s. The typical signs are listed below:3

  • forget about recent conversations or events
  • misplace items
  • forget the names of places and objects
  • have trouble thinking of the right word
  • ask questions repetitively
  • show poor judgement
  • become less flexible and more hesitant to try new things

As the disease progresses, the symptoms will gradually get worse. Memory problems will get worse which can make it difficult for the person who suffers with the disease to remember names of their loved ones, recent events and even remember birthdays and anniversaries. More symptoms such as the following will develop;3

  • increasing confusion and disorientation – for example, getting lost, or wandering and not knowing what time of day it is
  • obsessive, repetitive or impulsive behaviour
  • delusions or feeling paranoid and suspicious about carers or family members
  • problems with speech or language
  • disturbed sleep
  • changes in mood
  • difficulty performing simple tasks and may need additional support e.g. help with eating, getting dressed etc.

In the later stages of Alzheimer’s disease, the symptoms become increasingly severe and patients will need full-time care and assistance. It will be problematic for the individual to do basic everyday tasks such as getting changed, going to the toilet, getting washed and feeding themselves. They could lose their speech, and have difficulty eating and swallowing which can result in severe weight loss.

How Randox can help

Randox want to help. Our Evidence immunoanalyser has revolutionised laboratory screening worldwide with the capability to process 3,960 tests per hour and a sample capacity of 360. We offer the Apolipoprotein E4 (ApoE4) Array for Alzheimer’s genetic risk assessment, which is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.

For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email info@randoxbiosciences.com       

 

  1. https://www.alzheimers.org.uk/about-dementia/types-dementia/alzheimers-disease
  2. https://www.dementiastatistics.org/statistics-about-dementia/prevalence/
  3. https://www.nhs.uk/conditions/alzheimers-disease/symptoms/

 

 

 

 

 

 

 

 

 


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×